Introduction {#s0005}
============

CT colonography (CTC) is an alternative to optical colonoscopy (OC) for colorectal evaluation, including cancer screening and diagnostic evaluation. Although CTC demonstrates a per patient sensitivity of 0.78 in the detection of adenomas at least 6 mm, and an overall sensitivity of 89% in the detection of polyps at least 6 mm in diameter ([@bb0005], [@bb0010]) it may be safer than OC given that CTC does not involve passage of an endoscope or require sedation. Prior case series suggest low rates of gastrointestinal perforation and chest pain among patients who receive CTC; particularly in the screening population ([@bb0015], [@bb0020], [@bb0025]). However, there is a paucity of population based studies directly evaluating the risk of adverse events following CTC among the elderly where the risks are thought to be higher ([@bb0030], [@bb0035], [@bb0040], [@bb0045], [@bb0050], [@bb0055], [@bb0060]). This lack of data about the risks and benefits of CTC in the older population, in addition to concerns over the cost effectiveness of this modality, was cited in the Centers for Medicare and Medicaid Services (CMS) decision to deny coverage for screening CTC in March 2009 ([@bb0065], [@bb0070]).

Given this background, our objective was to evaluate the risks of gastrointestinal and cardiovascular events among symptomatic and asymptomatic outpatient Medicare beneficiaries who received CTC as their first method of colorectal evaluation during the two years preceding this CMS coverage determination; January 2007 through December 2008. Adverse events known to be associated with OC were selected as OC is the traditional method of colorectal evaluation. We focused on patients undergoing initial CTC to capture adverse events attributable to the CTC and to any subsequent testing within 30 days (including OC with or without biopsy ([@bb0045], [@bb0050], [@bb0075])) driven by the findings of the CTC. To provide clinical context CTC patients were compared to a cohort of patients who received initial OC and also stratified by asymptomatic (i.e. screening) and symptomatic (i.e. diagnostic) indications ([@bb0015], [@bb0025]).

Materials & methods {#s0020}
===================

Design overview {#s0025}
---------------

This Health Insurance Portability and Accountability Act compliant study using de-identified Medicare claims data was exempt from institutional review board approval. We performed a retrospective cohort study of all Medicare beneficiaries ≥ 66 years of age in the United States with a claim for CTC between January 2007 and December 2008 and a randomly selected group of patients with a claim for OC during the same time period, matched 9:1 by county of residence and year of colorectal evaluation. Approximately 98% of adults in the United States ages 65 and older are enrolled in Medicare, making Medicare data a robust source of health care utilization ([@bb0080]). Adverse events resulting in an emergency department visit or inpatient admission 30 days following either procedure were determined from Medicare Provider Analysis and Review, Outpatient and Carrier files using appropriate Current Procedural Terminology/Healthcare Common Procedure Coding System (CPT/HCPCS) and International Classification of Disease, Ninth Edition, Clinical Modification (ICD-9-CM) codes ([e-Table 1](#ec0005){ref-type="supplementary-material"}). We used a 30 day time interval for the assessment of complications to ensure a comparable follow-up interval in both cohorts based on prior data about complications from OC ([@bb0045]). Claims were also used to identify comorbidities associated with increased likelihood of adverse events in the year preceding either CTC or OC and comparable adverse events in the preceding 90 days. The analysis focused on patients who had either initial CTC, defined as no OC on the same day or within the prior 12 months, or initial OC, defined as no OC within the prior 12 months. Although 14% of the initial CTC patients in our study underwent OC within the 12 months after CTC, similar to published rates of 13--15% in the literature ([@bb0085], [@bb0090]), only 3% (187/6114) of initial CTC patients received OC within 30 days. Due to this small sample size a separate analysis of adverse events among patients who received OC within 30 days of CTC was not performed. However, additional analyses stratified patients by asymptomatic (i.e. screening) and symptomatic (i.e. diagnostic) indications using ICD-9 codes from the CTC or OC claim, based on a previously utilized algorithm ([@bb0095], [@bb0100]); a full list of codes is provided in [e-Table 1](#ec0005){ref-type="supplementary-material"}.

Setting and participants {#s0030}
------------------------

We excluded patients (a) enrolled in a Medicare Health Maintenance Organization within the year preceding or 30 days following CTC (n = 7429); or (b) disenrolled from Medicare Part A or B coverage during the same time interval (n = 558). Similar to prior methodology ([@bb0045]), we excluded patients with a significant prior colonic disease that increased the risk of perforation including Crohn\'s disease or ulcerative colitis (n = 2067), prior colorectal cancer (n = 6385), or diverticulitis in the preceding year (n = 11,169). Because the objective of our study was to evaluate patients who received CTC as the first method of colorectal evaluation we excluded patients who received CTC with OC either in the prior 12 months (n = 3595) or on the same day (n = 3197). Similarly, OC patients who received OC within the prior 12 months were excluded (n = 1994). We also excluded patients with more than one OC within 30 days of the initial OC or CTC (n = 6). Eighteen patients were excluded for CTC claims in the year preceding OC or CTC and thirteen patients were excluded for incomplete billing data. No patients were excluded on the basis of an incomplete procedure. The final study population was comprised of 153,316 patients ([Fig. 1](#f0005){ref-type="fig"}). These 153,316 patients included 3609 CTC and 115,691 OC patients from a prior publication ([@bb0100]). Differences in study populations are due to inclusion and/or exclusion criteria stemming from the disparate foci of these publications.

Outcomes and follow-up {#s0035}
----------------------

Four groups of adverse events requiring emergency department visits or inpatient admissions were identified in the 30 days following either procedure: lower gastrointestinal bleeding or administration of blood transfusions (excluding patients with transfusions performed 90 days prior to either procedure), gastrointestinal perforation, other gastrointestinal events (paralytic ileus, nausea, vomiting and dehydration, abdominal pain), and cardiovascular events (myocardial infarction or angina; arrhythmias; congestive heart failure \[CHF\]; cardiac or respiratory arrest; or syncope, hypotension, or shock). These adverse events were chosen as they have been associated with complications of OC, which is the traditional method of colorectal evaluation. Similar adverse events in the 90 days preceding CTC or OC were also recorded. Death within 30 days was evaluated, although cause of death cannot be inferred from claims data.

We accounted for common comorbidities associated with these adverse events using claims data from the year preceding CTC or OC including: atrial fibrillation/flutter, congestive heart failure,chronic pulmonary disease, stroke, diabetes, renal failure, diverticulosis, and obesity ([@bb0035], [@bb0045], [@bb0105]).

Sociodemographic characteristics including gender, age, and race were obtained from beneficiary summary files. Age was categorized into three groups (66--74, 75--84, and ≥ 85 years) and race into five groups (White, Black, Hispanic, Asian, and other).

Statistical analysis {#s0040}
--------------------

Chi-square analysis was used to compare sociodemographic and clinical characteristics, unadjusted risks of adverse events, and mortality within 30 days between patients who received initial CTC and OC. Unadjusted risks of adverse events were included as these data have not been previously reported using claims data. Given the cohort study design a generalized linear regression with a logit link and binomial distribution was used to estimate the odds ratios (OR) of adverse events between patients undergoing CTC and OC by indication (i.e. symptomatic versus asymptomatic) controlling for differences in patient characteristics including gender, age, race, comorbidities associated with studied adverse events, and adverse events in the preceding 90 days. Due to low event rates for the targeted adverse events there is limited concern of overestimation of the risk ratio, which is approximated by the OR in cohort studies. Statistical significance was declared for results with a two-sided p-value of \< 0.05. We used STATA, version 11 (STATA Corp) for all statistical analyses.

Results {#s0010}
=======

The final cohort included 6114 initial CTC outpatients with a mean age of 76.7 years (age range, 66--103 years; 2223 males \[mean age 77; age range 66--96\]; 3891 females \[mean age 77; age range 66--103\]) and 149,202 initial OC outpatients with a mean age of 74.4 years (age range, 66--104 years; 67,586 males \[mean age 74; age range 66--101\]; 81,616 females \[mean age 75; age range 66--104\]). Women, patients \> 75 years of age and Whites were more likely to receive CTC as their initial method of colorectal evaluation than OC ([Table 1](#t0005){ref-type="table"}). Patients undergoing initial CTC had a higher prevalence of comorbidities than patients undergoing initial OC, except for diabetes, diverticulosis and obesity. Among patients referred to initial CTC, with or without OC in the subsequent 30 days, the unadjusted risk of lower gastrointestinal bleeding per 1000 patients was 12.4, of perforation was 0.7, of other gastrointestinal events was 18.0 and of cardiovascular events was 45.5. Of note, perforation rates were low in both cohorts (4/6114 \[0.7%\] initial CTC and 181/149,202 \[1.2%\], initial OC). Similar proportions of patients died within 30 days in both cohorts.

Multivariate regression was performed to account for differences in gender, age, race, comorbidities associated with adverse events, and adverse events in the preceding 90 days. This revealed a higher risk of lower gastrointestinal bleeding, other gastrointestinal events and cardiovascular events among patients who underwent initial OC compared to initial CTC in the subsequent 30 days (OR 1.91 95CI \[1.47,2.49\], OR 1.35 95CI \[1.07,1.69\] and OR 1.38 95CI \[1.18,1.62\], respectively), but no difference in the risk of perforation ([Table 2](#t0010){ref-type="table"}). Similarly, even with adjustment for age, patients greater than 75 years who received either CTC or OC demonstrated a higher risk of lower gastrointestinal bleeding, other gastrointestinal events, and cardiovascular events than patients less than 75 years (OR 2.98 95CI \[2.61,3.41\], OR 1.39 95CI \[1.26,1.53\], and OR 1.44 95CI \[1.33,1.55\], respectively).

We also examined whether this pattern differed depending on the presence of symptoms. Higher unadjusted adverse event rates per 1000 patients were demonstrated among those with symptoms relative to those without symptoms within both cohorts ([Table 3](#t0015){ref-type="table"}). Following adjustment for gender, age, race, comorbidities associated with adverse events, and adverse events in the preceding 90 days, symptomatic patients referred to initial OC were found to have higher adjusted rates of lower gastrointestinal bleeding, other gastrointestinal events and cardiovascular events compared to symptomatic patients referred to initial CTC, with or without OC in the subsequent 30 days (OR 1.92 95CI \[1.47, 2.51\], OR 1.35 95CI \[1.07,1.70\], OR 1.43 95CI \[1.22, 1.68\], respectively) ([Table 4](#t0020){ref-type="table"}). Again, even with adjustment for age, higher rates of lower gastrointestinal bleeding, other gastrointestinal events and cardiovascular events were demonstrated among symptomatic patients greater than 75 years compared to patients less than 75 years (OR 2.70 95CI \[2.43,3.21\], OR 1.77 95CI \[1.53,2.05\], OR 2.37 95CI \[2.14,2.63\], respectively) ([Table 4](#t0020){ref-type="table"}). A similar pattern was observed within the asymptomatic cohort, but did not reach significance.

Discussion {#s0015}
==========

Our study demonstrates that patients ≥ 66 years of age who undergo initial CTC, with or without subsequent OC within 30 days, have lower risks of lower gastrointestinal bleeding, other gastrointestinal events and cardiovascular events compared to patients who undergo initial OC. However, the risk of perforation does not differ between initial CTC and OC. This pattern is similar among symptomatic, asymptomatic and older patients, although it did not reach significance for asymptomatic patients.

The findings in this population based study differ somewhat from prior case series demonstrating lower unadjusted rates of perforation among patients who undergo CTC (0.00--0.05%) ([@bb0015], [@bb0110]) and of cardiovascular events (0.05--0.06 per 1000 diagnostic CTC procedures) ([@bb0015], [@bb0020]). Differences in our results may reflect limitations of prior study populations, follow up interval, or measurement approach. Alternatively, these findings may reflect the small number of perforations identified in our study; particularly within the CTC cohort. Although we used the same methodology to identify perforations in both cohorts (i.e., emergency department visits and hospitalizations), CTC is more sensitive to sub-clinical perforation than OC due to the ability to visualize small amount of pneumoperitoneum ([@bb0115]). It is reassuring that our results are similar to perforation rates from a study where patients with pneumoperitoneum on CTC were referred to the emergency department (0.6 per 1000 CTC procedures) ([@bb0030]), which resembles our measurement approach. Our results also extend the previously published literature about the risks of adverse events from CTC among Medicare patients in that we are the first study to assess the risk of lower gastrointestinal bleeding following CTC.

Given that clinicians and patients desire data on the risks of initial CTC relative to initial OC, we have provided comparative data between these two procedures. Our analyses suggest that patients who undergo initial CTC, with or without subsequent OC, may experience lower rates of serious gastrointestinal, other gastrointestinal and cardiovascular events compared to patients who receive initial OC. This finding is intuitively reasonable, given that CTC does not require sedation and the intention of CTC is to selectively refer the approximately 8--15% of patients with suspected clinically significant polyps (\> 6 mm) and masses to OC for further evaluation ([@bb0110], [@bb0085], [@bb0090]). However, it is important to recognize that we were unable to fully adjust for differences between the groups based upon the information available in claims data. Patients who receive CTC are generally sicker than patients who receive OC ([@bb0100]). Furthermore, given the standard CTC technique, which does not include intravenous contrast, the use of a 30 day time interval is conservative and may include adverse events not directly related to this procedure. As such, our results may underestimate the differences between these two examinations.

Even after adjustment, we found that the risk of adverse events following CTC depends upon patient age (comparing patients 75 and older to patients under 75). Higher risk of lower gastrointestinal bleeding and cardiovascular events among patients older than 75 years who undergo colorectal evaluation are concordant with prior studies evaluating OC ([@bb0035], [@bb0040], [@bb0045], [@bb0050]), but has not previously been demonstrated for CTC. Both the US Preventive Services Task Force and the American College of Physicians recommend against routine screening of patients older than 75 due to increased risk of complications, competing causes of mortality and demonstrated benefit at least 7 years after screening ([@bb0120], [@bb0125]). Our findings support the inclusion of CTC in these recommendations.

Our study has several limitations. We used billing codes from Medicare claims rather than medical record review to determine adverse events. No studies validating the use of billing claims for CTC have been reported. However, prior studies have demonstrated high sensitivity and specificity for the assessment of procedures, including endoscopy, using Medicare claims compared to medical charts ([@bb0130], [@bb0135], [@bb0140]) and high likelihood of identifying diagnoses and select adverse events in Medicare claims ([@bb0145]). It is reassuring that our unadjusted adverse event risks among the OC cohort are similar to prior studies ([@bb0045]). We did not perform a randomized control trial, and there are likely to be unmeasured confounders or selection effects that we were unable to include in our adjustments. The technique utilized for CTC cannot be derived from claims data but is potentially important given that manual insufflation, luminal disease and use of a rectal balloon are associated with perforation ([@bb0015], [@bb0020], [@bb0030], [@bb0115]). Some of the adverse events specific to CT, such as radiation risk, cannot be measured with claims data. Although our findings may not generalize to younger patients, colorectal cancer is predominantly a disease of the elderly.

In conclusion, our study demonstrates that adverse event rates following initial CTC among the elderly are low, with the greatest risk for cardiovascular events. Rates of lower gastrointestinal bleeding, other gastrointestinal events and cardiovascular events are lower following initial CTC, with or without subsequent OC, than following initial OC; similar rates of perforation may stem from the small number of perforations in both cohorts. A similar pattern was demonstrated among patients \> 75 years of age and those with symptoms referable to colorectal cancer. These data can help primary care providers and patients seeking to understand complications associated with these methods of colorectal cancer screening and targeted diagnostic evaluation.

The following is the Supplementary data related to this article.Electronic Table 1Identification codes for all procedures and diagnoses.
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###### 

Frequency of Medicare outpatient characteristics and unadjusted adverse events within 30 days of receiving initial CT colonography (CTC) or initial optical colonoscopy (OC) between January 2007 and December 2008, (%).

                                                                                    Initial CTC   Initial OC       p value
  --------------------------------------------------------------------------------- ------------- ---------------- ---------
  Gender                                                                                                           \< .001
   Male                                                                             2223 (36.4)   67,586 (45.3)    
   Female                                                                           3891 (63.6)   81,616 (54.7)    
  Age                                                                                                              \< .001
   66--74                                                                           2500 (40.9)   82,411 (55.2)    
   75--84                                                                           2700 (44.2)   55,893 (37.5)    
   ≥ 85                                                                             914 (14.9)    10,898 (7.3)     
  Race                                                                                                             \< .001
   White                                                                            5688 (93.0)   130,481 (87.5)   
   Black                                                                            239 (3.9)     10,133 (6.8)     
   Other [a](#tf0005){ref-type="table-fn"}                                          78 (1.3)      2946 (2.0)       
   Asian                                                                            52 (0.9)      3197 (2.1)       
   Hispanic                                                                         57 (0.9)      2445 (1.6)       
  Comorbidities associated with adverse events                                                                     
   Atrial fibrillation/flutter                                                      1610 (26.3)   18,813 (12.6)    \< .001
   Congestive heart failure                                                         1298 (21.2)   19,735 (13.2)    \< .001
   Chronic pulmonary disease                                                        1759 (28.8)   34,149 (22.9)    \< .001
   Diabetes                                                                         1729 (28.3)   45,040 (30.2)    0.001
   Stroke                                                                           1419 (23.2)   24,457 (16.4)    \< .001
   Renal disease                                                                    636 (10.4)    12,827 (8.6)     \< .001
   Diverticulosis                                                                   2617 (42.8)   85,437 (57.3)    \< .001
   Obesity                                                                          298 (4.9)     8010 (5.4)       0.092
  Unadjusted adverse events within 30 days (risk per 1000 Medicare beneficiaries)                                  
   Gastrointestinal bleeding/transfusion                                            76 (12.4)     2471 (16.6)      0.013
   Perforation                                                                      4 (0.7)       181 (1.2)        0.214
   Other GI                                                                         110 (18.0)    2692 (18.0)      0.997
   Paralytic ileus                                                                  11 (1.8)      573 (3.8)        0.011
   Nausea, vomiting or dehydration                                                  75 (12.3)     1721 (11.4)      0.623
   Abdominal pain                                                                   34 (5.6)      695 (4.7)        0.311
   Cardiovascular disease                                                           278 (45.5)    5167 (34.6)      \< .001
   MI or angina [b](#tf0010){ref-type="table-fn"}                                   49 (8.0)      1112 (7.5)       0.617
   Arrhythmias                                                                      148 (24.2)    2754 (18.5)      0.001
   CHF                                                                              119 (19.5)    1874 (12.6)      \< .001
   Cardiac or respiratory arrest[c](#tf0015){ref-type="table-fn"}                   28 (4.6)      544 (3.6)        0.238
   Syncope, hypotension or shock                                                    49 (8.0)      945 (6.3)        0.106
  Mortality                                                                                                        
   Death within 30 days                                                             21 (0.3)      499 (0.3)        0.905

Other includes Unknown and Native American.

Including chest pain.

Not including shortness of breath.

###### 

Regression analysis of adverse events among Medicare outpatients who received initial CT colonography (CTC) or initial optical colonoscopy (OC) between January 2007 and December 2008[a](#tf0020){ref-type="table-fn"}.

                                     Gastrointestinal bleed   Perforation     Other gastrointestinal events   Cardiovascular events                                                 
  ---------------------------------- ------------------------ --------------- ------------------------------- ----------------------- ------ --------------- ------ --------------- --
  *Total population (n = 155,316)*                                                                                                                                                  
  Type of examination                                                                                                                                                               
   Initial CTC (n = 6114)                                                                                                                                                           
   Initial OC (n = 149,202)          1.91                     \[1.47,2.49\]   2.62                            \[0.84,8.22\]           1.35   \[1.07,1.69\]   1.38   \[1.18,1.62\]   
  Age                                66--74 (ref)                                                                                                                                   
  75--84                             1.38                     \[1.24,1.53\]   1.18                            \[0.84,1.66\]           1.39   \[1.26,1.53\]   1.44   \[1.33,1.55\]   
  ≥ 85                               2.98                     \[2.61,3.41\]   0.75                            \[0.38,1.46\]           1.87   \[1.63,2.15\]   2.54   \[2.29,2.80\]   

Regression analyses are adjusted for gender, age, race, comorbidities associated with adverse events (i.e. atrial fibrillation/flutter, congestive heart failure, chronic pulmonary disease, diabetes, stroke, renal disease, diverticulosis, obesity), and adverse events in preceding 90 days.

###### 

Unadjusted risk per 1000 Medicare outpatients for adverse events within 30 days of initial CT colonography (CTC) or initial optical colonoscopy (OC) received between January 2007 and December 2008 by indication.

                                                                     Initial CTC   Initial OC                                    
  ------------------------------------------------------------------ ------------- ------------ ----- ------ ----- ------ ------ ------
  Gastrointestinal bleeding                                          4             2.9          72    15.2   371   6.9    2100   22.1
  Perforation                                                        1             0.7          3     0.6    46    0.9    135    1.4
  Other GI                                                           5             3.6          105   22.2   311   5.8    2381   25
   Ileus                                                             0             0            11    2.3    76    1.4    497    5.2
   Nausea, vomiting or dehydration                                   4             2.9          71    15     169   3.1    1552   16.3
   Abdominal pain                                                    2             1.4          32    6.8    107   2      588    6.2
  CVD events                                                         26            18.8         252   53.3   610   11.3   4557   47.9
   MI or angina[a](#tf0025){ref-type="table-fn"}                     4             2.9          45    9.5    176   3.3    936    9.8
   Arrhythmias                                                       14            10.1         134   28.3   329   6.1    2425   25.5
   CHF                                                               5             3.6          114   24.1   94    1.7    1780   18.7
   Cardiac or respiratory arrest [b](#tf0030){ref-type="table-fn"}   1             0.7          27    5.7    43    0.8    501    5.3
                                                                     9             6.5          40    8.5    149   2.8    796    8.4

Including chest pain.

Not including shortness of breath.

###### 

Regression analysis of adverse events among Medicare outpatients who received initial CT colonography (CTC) or initial optical colonoscopy (OC) between January 2007 and December 2008 by indication[a](#tf0035){ref-type="table-fn"}.

                                           Gastrointestinal bleed   Perforation     Other gastrointestinal events   Cardiovascular events                                                 
  ---------------------------------------- ------------------------ --------------- ------------------------------- ----------------------- ------ --------------- ------ --------------- --
  *Asymptomatic population (n = 55,423)*                                                                                                                                                  
  Type of examination                                                                                                                                                                     
   Initial CTC (n = 1384)                                                                                                                                                                 
   Initial OC (n = 54,039)                 2.29                     \[0.76,6.90\]   3.53                            \[0.20,63.54\]          2.36   \[0.89,6.30\]   1.22   \[0.74,2.01\]   
  Age                                      66--74 (ref)                                                                                                                                   
  75--84                                   1.14                     \[0.87,1.48\]   1.02                            \[0.49,2.14\]           0.92   \[0.70,1.22\]   1.35   \[1.10,1.64\]   
  ≥ 85                                     1.49                     \[0.81,2.75\]   1.99                            \[0.45,8.69\]           1.22   \[0.68,2.20\]   1.56   \[1.05,2.32\]   
                                                                                                                                                                                          
  *Symptomatic population (n = 99,893)*                                                                                                                                                   
  Type of examination                                                                                                                                                                     
   Initial CTC (n = 4730)                                                                                                                                                                 
   Initial OC (n = 95,163)                 1.92                     \[1.47,2.51\]   2.55                            \[0.73,8.94\]           1.35   \[1.07,1.70\]   1.43   \[1.22,1.68\]   
  Age                                      66--74 (ref)                                                                                                                                   
  75--84                                   1.36                     \[1.21,1.52\]   1.20                            \[0.81,1.79\]           1.40   \[1.26,1.56\]   1.38   \[1.27,1.50\]   
  ≥ 85                                     2.79                     \[2.43,3.21\]   0.67                            \[0.33,1.37\]           1.77   \[1.53,2.05\]   2.37   \[2.14,2.63\]   

Regression analyses are adjusted for gender, age, race, comorbidities associated with adverse events (i.e. atrial fibrillation/flutter, congestive heart failure, chronic pulmonary disease, diabetes, stroke, renal disease, diverticulosis, obesity), and adverse events in preceding 90 days.
